8 results
Primary:To estimate the treatment effects of vildagliptin 50 mg PO BID on 24h weighted-mean glucose (WMG), using CGM and plasma glucose, collected at the end of a two-week treatment period.Secondary:1) To estimate the treatment effects of…
Is addition of a DPP4-inhibitor (vildagliptin) beneficial in type 2 diabetic patients, starting on once daily long-acting insulin in combination with 2 dd metformin. Primary end point is necessary dose of insulin to remain glycemic control.…
To optimize glycemic control in acute ischemic stroke patients.
This multicentre phase III study is designed to assess the efficacy and safety of recombinant versus E-Coli derived Aaparaginase from Medac, during treatment of children with newly diagnosed ALL according to the DCOG ALL-10 protocol.Futhermore: To…
Primary Objective: To determine whether a four week treatment with vildagliptin compared to acarbose improves endothelial dysfunction in patients with type 2 diabetes mellitus.Secondary Objective(s):-To determine the effect of vildagliptin on plasma…
(1) To examine whether the exposure to BWL yields clinically significant reductions in CRF compared to exposure to dim white light in (non-)Hodgkin survivors. (2) To examine the effect of exposure to BWL compared to DWL on sleep quality and…
PrimaryThe 3 months* effect of Vildagliptin on insulin synthesis and storage capacitySecondaryThe 3 months* effect of vildagliptin on- Glucose, insulin, C-peptide levels- Hormonal axes, most importantly GLP1 and GIP and Glucagon- Body weight, body…
The purpose of this study is to determine the safety and efficacy of Nilotinib and Vildagliptin as combination therapy in optimal dosage. In addition, it is investigated whether the addition of Vildagliptin to Nilotinib treatment causes the…